128 related articles for article (PubMed ID: 30653813)
1. Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.
Scridon A; Mărginean A; Huțanu A; Chinezu L; Gheban D; Perian M; Vântu A; Gherțescu D; Fișcă PC; Șerban RC; Chevalier P; Dobreanu D
J Thromb Haemost; 2019 Mar; 17(3):538-550. PubMed ID: 30653813
[TBL] [Abstract][Full Text] [Related]
2. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Lee IO; Kratz MT; Schirmer SH; Baumhäkel M; Böhm M
J Pharmacol Exp Ther; 2012 Nov; 343(2):253-7. PubMed ID: 22837011
[TBL] [Abstract][Full Text] [Related]
3. Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
Martischnig AM; Mehilli J; Pollak J; Petzold T; Fiedler AK; Mayer K; Schulz-Schüpke S; Sibbing D; Massberg S; Kastrati A; Sarafoff N
Biomed Res Int; 2015; 2015():798486. PubMed ID: 26229963
[TBL] [Abstract][Full Text] [Related]
4. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice.
Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2020 Jan; 124():106632. PubMed ID: 31759113
[TBL] [Abstract][Full Text] [Related]
5. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Achilles A; Mohring A; Dannenberg L; Grandoch M; Hohlfeld T; Fischer JW; Levkau B; Kelm M; Zeus T; Polzin A
J Thromb Haemost; 2017 Mar; 15(3):473-476. PubMed ID: 27992120
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy.
Sokol J; Nehaj F; Ivankova J; Mokan M; Mokan M; Stasko J
Scand Cardiovasc J; 2018 Aug; 52(4):227-231. PubMed ID: 29842807
[TBL] [Abstract][Full Text] [Related]
8. Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran.
Nehaj F; Sokol J; Mokan M; Ivankova J; Mokan M
Clin Appl Thromb Hemost; 2018 Mar; 24(2):268-272. PubMed ID: 28703014
[TBL] [Abstract][Full Text] [Related]
9. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
10. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Olivier CB; Weik P; Meyer M; Weber S; Anto-Michel N; Diehl P; Zhou Q; Geisen U; Bode C; Moser M
Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
12. The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation.
Trabold K; Makhoul S; Gambaryan S; van Ryn J; Walter U; Jurk K
Thromb Haemost; 2019 Jun; 119(6):916-929. PubMed ID: 31005062
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors.
Wang S; Dai P; Xu Y; Chen Q; Zhu Q; Gong G
Arch Pharm (Weinheim); 2015 Aug; 348(8):595-605. PubMed ID: 26120827
[TBL] [Abstract][Full Text] [Related]
14. [Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y; Lu XX; Wang ZY; Dai L; Shen WH; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3299-301. PubMed ID: 17313817
[TBL] [Abstract][Full Text] [Related]
15. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats.
Ersöz G; Yakaryilmaz A; Turan B
Thromb Res; 2003; 111(6):363-7. PubMed ID: 14698654
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
18. Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice.
Hamilton JR; Cornelissen I; Mountford JK; Coughlin SR
Atherosclerosis; 2009 Aug; 205(2):427-32. PubMed ID: 19217621
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
20. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
